Kolexia
Treilleux Isabelle Anatomie et cytologie
Treilleux Isabelle
Anatomie et cytologie
Centre Léon-Bérard
Lyon, France
224 Activités
3 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de l'ovaire Carcinomes Récidive tumorale locale Métastase tumorale Adénocarcinome Tumeurs de l'endomètre Sarcomes Tumeurs des cordons sexuels et du stroma gonadique

Collaborateurs

Voir plus
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Tredan Olivier
Tredan Olivier
Centre Léon-Bérard, Lyon, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
AstraZeneca
18 collaboration(s)
Dernière en 2023
MSD
11 collaboration(s)
Dernière en 2023
Roche
4 collaboration(s)
Dernière en 2023
GSK
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
VICTORIA: A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Essai Clinique (Centre Léon-Bérard)   12 février 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Science translational medicine   24 janvier 2024
A curious biphasic breast lesion.
Annales de pathologie   16 janvier 2024
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
British journal of cancer   05 janvier 2024
20P Deciphering tumor microenvironment heterogeneity between primary tumor and metastases in high grade serous ovarian cancer (HGSC) to predict response to immunotherapy (IT): Analyses from the NeoPembrOv/GINECO phase II trial
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
180P Immunogenomic profiling of the randomized NeoPembrOv clinical trial reveals the VEGFR2 angiogenic axis as a promising actionable target to overcome immunoresistance of high-grade ovarian carcinomas
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
Histopathology   21 novembre 2023
MDR1-EXPRESSING CD4 T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE.
Journal for immunotherapy of cancer   10 novembre 2023
Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours.
Bulletin du cancer   06 octobre 2023
An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers.
Cancer research communications   02 octobre 2023